CLOSE
SEARCH FOR
Book a Meeting

Bi-specific Non-IgG Antibody Service

More Info

As a leader in the field of antibody research and development, Creative Biolabs is committed to providing the most comprehensive bi-specific antibody (BsAb) antibody services for our global clients. Attracted by the distinctive advantages of BsAb and non-IgG antibodies (mainly IgA, IgM, and IgE), scientists at Creative Biolabs are trying their best to develop potential bi-specific non-IgG antibodies in recent years.

Brief Background of Non-IgG BsAb

BsAb is a category of special antibody that can simultaneously react with two different targets (including antigens, epitopes, ligands, receptors, and cells). BsAbs can be designed and produced in many structures and formats (see in Fig.1), such as bispecific single-domain antibody, bispecific diabody, bispecific Fab domain, etc., which are generally divided into two classes: IgG-like (structure containing an Fc region) and non-IgG-like (structures lacking an Fc region). These broad-spectrum BsAbs are extensively applied for diagnosis, prophylaxis, drug delivery, and therapy, particularly for cancer immunotherapy, since their higher efficiency by binding to a cytotoxic cell and a target simultaneously. There are several BsAbs have been approved for clinical anti-tumor treatment, moreover, over 50 promising BsAbs are in pre-clinical and clinical trials for various malignancies during the last decade.

The zoo of bispecific antibody formats.Fig.1 The zoo of bispecific antibody formats. (Brinkmann, 2017)

Development of BsAb is an extremely fast-growing field with innovative formats emerging constantly. As a senior biotechnology company with strong comprehensive strength, Creative Biolabs endeavors to develop the most comprehensive and the highest quality BsAb service. Specialists in our company are dedicated to producing and developing bi-specific non-IgG antibodies considering that:

(i) From BsAb: more binding sites, stronger binding ability, and higher cytotoxic effects.

(ii) From non-IgG antibodies: IgA, IgM, and IgE exhibit their unique properties (mucosal immunity, complement activation, etc.) and certain advantages in the treatment of certain diseases.

(iii) From applications: BsAbs currently in clinical usage or under preclinical tests are all derived from IgG antibody, none of them designed based on these non-IgG isotypes.

(iv) Others: BsAb can also be used as one of the non-IgG antibodies engineerings to optimize the performance of our diversiform non-IgG therapeutic antibodies.

What We Can Do About Bi-Specific Non-IgG Antibodies?

In order to discover more efficient therapeutic antibodies and offer more comprehensive service for academic and commercial needs of our universal customers, Creative Biolabs has established a dedicated team and a professional technical platform for non-IgG BsAbs development and services.

Based on our possessing non-IgG antibody platform and BsAb service system, we can support your bi-specific non-IgG antibody programs in many aspects, covering from initial bi-specific design and optimization to later production. According to your detailed requirements, our seasoned scientists start with BsAb design (e.g., target binding, isotype selection, mode of action), followed by optimization to improve their properties (half-life, size, stability, etc.), and production in quantities (recombinant DNA technology, hybrid-hybridoma technology, isotype converting, and conjugation).

Schematic overview of the different strategies used to generate bsAbs derived from the antigen-binding sites of two different antibodies.Fig.2 Schematic overview of the different strategies used to generate bsAbs derived from the antigen-binding sites of two different antibodies. (Kontermann, 2015)

Along with years of rich experience in offering innovative and sophisticated BsAb development services to meet customers' exact needs, Creative Biolabs is now confident in offering the customized bi-specific non-IgG antibodies and related services. Please do not hesitate to contact us for more details.

References

  1. Brinkmann, U.; Kontermann, R.E. The making of bispecific antibodies. MAbs. 2017, 9(2): 182-212.
  2. Kontermann, R.E.; Brinkmann, U. Bispecific antibodies. Drug Discovery Today. 2015, 7(20): 838-847.

KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.

Online Inquiry

For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.

CONTACT US

USA

Tel:

Fax:

Email:

Stay Up To Date
Subscribe

© 2022 Creative Biolabs All Rights Reserved